File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Pro-angiogenic activity of astragaloside IV in HUVECs in vitro and zebrafish in vivo
  • Basic View
  • Metadata View
  • XML View
TitlePro-angiogenic activity of astragaloside IV in HUVECs in vitro and zebrafish in vivo
 
AuthorsZhang, Y2
Hu, G2
Li, S2
Li, ZH2
Lam, CO2
Hong, SJ2
Kwan, YW4
Chan, SW3
Leung, GPH1
Lee, SMY2
 
Issue Date2012
 
PublisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/mmr/
 
CitationMolecular Medicine Reports, 2012, v. 5 n. 3, p. 805-811 [How to Cite?]
DOI: http://dx.doi.org/10.3892/mmr.2011.716
 
AbstractAstragaloside IV (AS-IV) is a natural product isolated from the Chinese medical herb, Radix Astragali, which has been reported to be a potential candidate for treating diseases associated with abnormal angiogenesis; however, the effect of AS-IV on angiogenesis and its underlying mechanisms are yet to be fully elucidated. In the present study, we investigated the angiogenic effect of AS-IV in vitro using human umbilical vein endothelial cells (HUVECs), and in vivo using zebrafish. AS-IV was found to stimulate the proliferation and migration of HUVECs in an XTT assay and a wound healing migration assay, respectively. Moreover, AS-IV stimulated the invasive ability of HUVECs and significantly increased the mean tube length of HUVECs in Matrigel. AS-IV induced an angiogenic response in HUVECs and enhanced mRNA expression of vascular endothelial growth factor (VEGF) and a VEGF receptor known as kinase--domain region/fetal liver kinase-1/VEGF receptor 2 (KDR/Flk-1/VEGFR2), as well as activation of Akt as demonstrated by quantitative real-time PCR and Western blot analysis, respectively. The AS-IV-induced proliferation of HUVECs was capable of being suppressed by a KDR inhibitor (SU5416) and an Akt inhibitor (SH-6). AS-IV also rescued blood vessel loss in Tg (fli-1:EGFP) zebrafish. Altogether, our results suggest that AS-IV exerts potential pro-angiogenic effects in vitro and in vivo, and that its pro-angiogenic activity probably involves both VEGF- and Akt-dependent signaling pathways.
 
DescriptionThe article can be viewed at http://www.spandidos-publications.com/10.3892/mmr.2011.716
 
ISSN1791-2997
2013 Impact Factor: 1.484
 
DOIhttp://dx.doi.org/10.3892/mmr.2011.716
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorZhang, Y
 
dc.contributor.authorHu, G
 
dc.contributor.authorLi, S
 
dc.contributor.authorLi, ZH
 
dc.contributor.authorLam, CO
 
dc.contributor.authorHong, SJ
 
dc.contributor.authorKwan, YW
 
dc.contributor.authorChan, SW
 
dc.contributor.authorLeung, GPH
 
dc.contributor.authorLee, SMY
 
dc.date.accessioned2012-08-16T05:56:14Z
 
dc.date.available2012-08-16T05:56:14Z
 
dc.date.issued2012
 
dc.description.abstractAstragaloside IV (AS-IV) is a natural product isolated from the Chinese medical herb, Radix Astragali, which has been reported to be a potential candidate for treating diseases associated with abnormal angiogenesis; however, the effect of AS-IV on angiogenesis and its underlying mechanisms are yet to be fully elucidated. In the present study, we investigated the angiogenic effect of AS-IV in vitro using human umbilical vein endothelial cells (HUVECs), and in vivo using zebrafish. AS-IV was found to stimulate the proliferation and migration of HUVECs in an XTT assay and a wound healing migration assay, respectively. Moreover, AS-IV stimulated the invasive ability of HUVECs and significantly increased the mean tube length of HUVECs in Matrigel. AS-IV induced an angiogenic response in HUVECs and enhanced mRNA expression of vascular endothelial growth factor (VEGF) and a VEGF receptor known as kinase--domain region/fetal liver kinase-1/VEGF receptor 2 (KDR/Flk-1/VEGFR2), as well as activation of Akt as demonstrated by quantitative real-time PCR and Western blot analysis, respectively. The AS-IV-induced proliferation of HUVECs was capable of being suppressed by a KDR inhibitor (SU5416) and an Akt inhibitor (SH-6). AS-IV also rescued blood vessel loss in Tg (fli-1:EGFP) zebrafish. Altogether, our results suggest that AS-IV exerts potential pro-angiogenic effects in vitro and in vivo, and that its pro-angiogenic activity probably involves both VEGF- and Akt-dependent signaling pathways.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.descriptionThe article can be viewed at http://www.spandidos-publications.com/10.3892/mmr.2011.716
 
dc.identifier.citationMolecular Medicine Reports, 2012, v. 5 n. 3, p. 805-811 [How to Cite?]
DOI: http://dx.doi.org/10.3892/mmr.2011.716
 
dc.identifier.doihttp://dx.doi.org/10.3892/mmr.2011.716
 
dc.identifier.epage811
 
dc.identifier.hkuros203461
 
dc.identifier.issn1791-2997
2013 Impact Factor: 1.484
 
dc.identifier.issue3
 
dc.identifier.pmid22179585
 
dc.identifier.scopuseid_2-s2.0-84863042713
 
dc.identifier.spage805
 
dc.identifier.urihttp://hdl.handle.net/10722/159769
 
dc.identifier.volume5
 
dc.languageeng
 
dc.publisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/mmr/
 
dc.relation.ispartofMolecular Medicine Reports
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAngiogenesis Inducing Agents - pharmacology
 
dc.subject.meshAnimals
 
dc.subject.meshAstragalus Plant - chemistry
 
dc.subject.meshCell Movement
 
dc.subject.meshCell Proliferation - drug effects
 
dc.subject.meshCells, Cultured
 
dc.subject.meshDrugs, Chinese Herbal - chemistry
 
dc.subject.meshGene Expression Regulation - drug effects
 
dc.subject.meshHuman Umbilical Vein Endothelial Cells - drug effects - metabolism
 
dc.subject.meshHumans
 
dc.subject.meshIndoles - pharmacology
 
dc.subject.meshNeovascularization, Physiologic - drug effects
 
dc.subject.meshPhosphatidylinositols - pharmacology
 
dc.subject.meshProto-Oncogene Proteins c-akt - antagonists & inhibitors - genetics - metabolism
 
dc.subject.meshPyrroles - pharmacology
 
dc.subject.meshReceptors, Vascular Endothelial Growth Factor - genetics - metabolism
 
dc.subject.meshSaponins - pharmacology
 
dc.subject.meshTriterpenes - pharmacology
 
dc.subject.meshVascular Endothelial Growth Factor A - genetics - metabolism
 
dc.subject.meshVascular Endothelial Growth Factor Receptor-2 - genetics - metabolism
 
dc.subject.meshZebrafish
 
dc.titlePro-angiogenic activity of astragaloside IV in HUVECs in vitro and zebrafish in vivo
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Zhang, Y</contributor.author>
<contributor.author>Hu, G</contributor.author>
<contributor.author>Li, S</contributor.author>
<contributor.author>Li, ZH</contributor.author>
<contributor.author>Lam, CO</contributor.author>
<contributor.author>Hong, SJ</contributor.author>
<contributor.author>Kwan, YW</contributor.author>
<contributor.author>Chan, SW</contributor.author>
<contributor.author>Leung, GPH</contributor.author>
<contributor.author>Lee, SMY</contributor.author>
<date.accessioned>2012-08-16T05:56:14Z</date.accessioned>
<date.available>2012-08-16T05:56:14Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Molecular Medicine Reports, 2012, v. 5 n. 3, p. 805-811</identifier.citation>
<identifier.issn>1791-2997</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/159769</identifier.uri>
<description>The article can be viewed at http://www.spandidos-publications.com/10.3892/mmr.2011.716</description>
<description.abstract>Astragaloside IV (AS-IV) is a natural product isolated from the Chinese medical herb, Radix Astragali, which has been reported to be a potential candidate for treating diseases associated with abnormal angiogenesis; however, the effect of AS-IV on angiogenesis and its underlying mechanisms are yet to be fully elucidated. In the present study, we investigated the angiogenic effect of AS-IV in vitro using human umbilical vein endothelial cells (HUVECs), and in vivo using zebrafish. AS-IV was found to stimulate the proliferation and migration of HUVECs in an XTT assay and a wound healing migration assay, respectively. Moreover, AS-IV stimulated the invasive ability of HUVECs and significantly increased the mean tube length of HUVECs in Matrigel. AS-IV induced an angiogenic response in HUVECs and enhanced mRNA expression of vascular endothelial growth factor (VEGF) and a VEGF receptor known as kinase--domain region/fetal liver kinase-1/VEGF receptor 2 (KDR/Flk-1/VEGFR2), as well as activation of Akt as demonstrated by quantitative real-time PCR and Western blot analysis, respectively. The AS-IV-induced proliferation of HUVECs was capable of being suppressed by a KDR inhibitor (SU5416) and an Akt inhibitor (SH-6). AS-IV also rescued blood vessel loss in Tg (fli-1:EGFP) zebrafish. Altogether, our results suggest that AS-IV exerts potential pro-angiogenic effects in vitro and in vivo, and that its pro-angiogenic activity probably involves both VEGF- and Akt-dependent signaling pathways.</description.abstract>
<language>eng</language>
<publisher>Spandidos Publications. The Journal&apos;s web site is located at http://www.spandidos-publications.com/mmr/</publisher>
<relation.ispartof>Molecular Medicine Reports</relation.ispartof>
<subject.mesh>Angiogenesis Inducing Agents - pharmacology</subject.mesh>
<subject.mesh>Animals</subject.mesh>
<subject.mesh>Astragalus Plant - chemistry</subject.mesh>
<subject.mesh>Cell Movement</subject.mesh>
<subject.mesh>Cell Proliferation - drug effects</subject.mesh>
<subject.mesh>Cells, Cultured</subject.mesh>
<subject.mesh>Drugs, Chinese Herbal - chemistry</subject.mesh>
<subject.mesh>Gene Expression Regulation - drug effects</subject.mesh>
<subject.mesh>Human Umbilical Vein Endothelial Cells - drug effects - metabolism</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Indoles - pharmacology</subject.mesh>
<subject.mesh>Neovascularization, Physiologic - drug effects</subject.mesh>
<subject.mesh>Phosphatidylinositols - pharmacology</subject.mesh>
<subject.mesh>Proto-Oncogene Proteins c-akt - antagonists &amp; inhibitors - genetics - metabolism</subject.mesh>
<subject.mesh>Pyrroles - pharmacology</subject.mesh>
<subject.mesh>Receptors, Vascular Endothelial Growth Factor - genetics - metabolism</subject.mesh>
<subject.mesh>Saponins - pharmacology</subject.mesh>
<subject.mesh>Triterpenes - pharmacology</subject.mesh>
<subject.mesh>Vascular Endothelial Growth Factor A - genetics - metabolism</subject.mesh>
<subject.mesh>Vascular Endothelial Growth Factor Receptor-2 - genetics - metabolism</subject.mesh>
<subject.mesh>Zebrafish</subject.mesh>
<title>Pro-angiogenic activity of astragaloside IV in HUVECs in vitro and zebrafish in vivo</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.3892/mmr.2011.716</identifier.doi>
<identifier.pmid>22179585</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84863042713</identifier.scopus>
<identifier.hkuros>203461</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-84863042713&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>5</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>805</identifier.spage>
<identifier.epage>811</identifier.epage>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. University of Macau
  3. Hong Kong Polytechnic University
  4. Chinese University of Hong Kong